Imkeldi is a drug owned by Shorla Oncology. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 27, 2040. Details of Imkeldi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11957681 | Liquid dosage forms of Imatinib |
Apr, 2040
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Imkeldi's patents.
Latest Legal Activities on Imkeldi's Patents
Given below is the list of recent legal activities going on the following patents of Imkeldi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 28 May, 2024 | US11957681 |
| Patent eCofC Notification | 28 May, 2024 | US11957681 |
| Mail Patent eCofC Notification | 28 May, 2024 | US11957681 |
| Email Notification | 28 May, 2024 | US11957681 |
| Email Notification | 15 May, 2024 | US11957681 |
| Mail Certificate of Correction Memo | 14 May, 2024 | US11957681 |
| Post Issue Communication - Certificate of Correction | 09 May, 2024 | US11957681 |
| Certificate of Correction Memo | 08 May, 2024 | US11957681 |
| Email Notification | 17 Apr, 2024 | US11957681 |
| Patent eGrant Notification | 16 Apr, 2024 | US11957681 |
US patents provide insights into the exclusivity only within the United States, but
Imkeldi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Imkeldi's family patents as well as insights into
ongoing legal events
on those patents.
Imkeldi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Imkeldi's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 27, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Imkeldi Generic API suppliers:
Imatinib Mesylate is the generic name for the brand Imkeldi. 16 different companies have already filed for the generic of Imkeldi, with Amneal Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Imkeldi's generic
Alternative Brands for Imkeldi
There are several other brand drugs using the same active ingredient (Imatinib Mesylate) as Imkeldi. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Novartis |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Imatinib Mesylate, Imkeldi's active ingredient. Check the complete list of approved generic manufacturers for Imkeldi
About Imkeldi
Imkeldi is a drug owned by Shorla Oncology. Imkeldi uses Imatinib Mesylate as an active ingredient. Imkeldi was launched by Shorla in 2024.
Approval Date:
Imkeldi was approved by FDA for market use on 22 November, 2024.
Active Ingredient:
Imkeldi uses Imatinib Mesylate as the active ingredient. Check out other Drugs and Companies using Imatinib Mesylate ingredient
Dosage:
Imkeldi is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 80MG BASE/ML | SOLUTION | Prescription | ORAL |